B+
Bull case
20%
Probability
Target price
$18.50
+28.7% vs current
ANIK
Anika TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$15.50
+7.8% vs current
B-
Bear case
25%
Probability
Target price
$10.00
-30.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-30
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.2
Score
AI commentary
Recent company news flow was constructive around the Q1 release, but the evidence set remains low-coverage and I could not confirm any trustworthy post-print analyst target or estimate revisions. No reliable post-print market-reaction datapoint was checked here, so the stock still looks more like a catalyst-driven monitoring name than a settled re-rating story.
RankAlpha Sentiment Codex - 2026-05-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31catalystQ1 operating rebound needs to hold into the next quarterMedium impact
The April 29 earnings release/10-Q showed Q1 revenue of $29.6m (+13% y/y), gross margin of 64% versus 56% a year ago, and adjusted EBITDA of $4.3m, which supports the operating-reset thesis if OEM timing and margin gains persist [#8-K-2026-04-29] [#10-Q-2026-04-30].
2026-09-30eventHyalofast PMA remains the clearest binary regulatory eventHigh impact
The 10-Q says the U.S. PMA was submitted on October 31, 2025 and that management is targeting a U.S. launch by 2027 pending FDA approval, so any FDA response or timing update could still move the stock materially [#10-Q-2026-04-30].
2026-12-31catalystCingal development progress preserves option value, but timing is execution-dependentHigh impact
The company says it is still engaging with the FDA and has initiated the preclinical and bioequivalence work needed for the Cingal path, making regulatory progress or slippage the main driver of longer-dated upside [#10-Q-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-30 • Updated nightlySource: Internal modelMethodology